SK bioscience and MSD Launch Major Zaire Ebolavirus Vaccine Initiative

SK bioscience has announced significant advancements in the development of a vaccine for the Zaire ebolavirus, bolstered by funding from the Coalition for Epidemic Preparedness Innovations (CEPI). This initiative comes as part of a collaboration with global pharmaceutical company MSD, which has secured up to USD 30 million from CEPI to facilitate key research and development activities.

Under this agreement, MSD will allocate the funding to its partners, including SK bioscience and Hilleman Laboratories. The latter is a joint venture between MSD and Wellcome, a global health research foundation. This collaboration aims to enhance the existing manufacturing process of the Zaire ebolavirus vaccine, which is currently complex and necessitates ultra-low temperature storage. These logistical challenges hamper vaccine distribution in remote regions where Ebola outbreaks frequently occur.

Improving the manufacturing yield and the vaccine’s thermostability is critical to making it more affordable and accessible. The project aims to enable a sustainable vaccine supply, contingent upon regulatory review and public health requirements. Hilleman Laboratories will spearhead the clinical development of the updated vaccine, while SK bioscience, in partnership with IDT Biologika, will refine the drug substance manufacturing process and the related drug product.

SK bioscience is dedicated to enhancing vaccine affordability and accessibility, particularly in low- and middle-income countries. The Zaire ebolavirus poses a significant threat, with frequent outbreaks reported in regions such as the Democratic Republic of the Congo, where survival rates hover around 50%. Recent outbreaks have highlighted the ongoing global risk of the virus, particularly in areas lacking adequate healthcare infrastructure.

Dr. Richard Hatchett, CEO of CEPI, emphasized the transformative progress made in combating Ebola. He stated, “In a single decade, the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks. CEPI’s support will help to enable a sustainable and accessible supply of MSD’s Zaire ebolavirus vaccine for years to come at a more affordable price.” This partnership aims to strengthen global defenses against one of humanity’s deadliest pathogens.

Jaeyong Ahn, CEO of SK bioscience, remarked on the importance of global collaboration in addressing infectious diseases like Ebola. He noted, “Through this CEPI-supported partnership, SK bioscience will continue to play a critical role in improving Zaire ebolavirus vaccine manufacturing and supply, contributing meaningfully to global health preparedness.”

SK bioscience has established a robust track record of collaboration with major global health organizations, including CEPI, the Gates Foundation, and the International Vaccine Institute (IVI). The company continues to leverage its integrated capabilities in development, manufacturing, and supply to expand its role in public health initiatives aimed at improving vaccine access worldwide.

SK bioscience remains committed to providing high-quality vaccines and better healthcare solutions, striving to make a meaningful impact on global health through innovative vaccine development and manufacturing processes.